Chandra Bhagat Pharma Receives In-Principle Approval for Preferential Issue
Chandra Bhagat Pharma Ltd 路 Others (Uncategorized) 路 13 Oct 2026, 6:01 pm
Chandra Bhagat Pharma Receives In-Principle Approval for Preferential Issue Chandra Bhagat Pharma Limited received in-principle approval from BSE on 12th Oct'26 for a preferential issue under Regulation 28(1) of SEBI LODR Regulations. The approval covers 66,00,000 warrants convertible into 66,00,000 equity shares of face value Rs. 10 each. The securities will be issued to promoter and non-promoter groups at a floor price of Rs. 44 per share, subject to post-issue formalities, statutory compliances, and listing applications within twenty days from allotment.
Original exchange filing (PDF)
More announcements from Chandra Bhagat Pharma Ltd
- Outcome of the Board Meeting held on 13th November, 2026. 路 13 Nov 2026
- Outcome of the Board Meeting held on 13th November, 2026 for approval of un-audited result as on 30th September, 2026. 路 13 Nov 2026
- Chandra Bhagat Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Un-audited Result for .... 路 13 Nov 2026
- The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Samir Ramkant Dave 路 27 Oct 2026
- The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Chintan Vijay Makhecha 路 27 Oct 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hemant Chandravadan Bhagat & PACs 路 26 Oct 2026
- Please find attached disclosure under Reg 30 of SEBI (LODR) Regulations, 2015 for your reference. 路 22 Oct 2026
- Certificate for Non_Applicability of Corporate Governance Certificate for the quarter ended 30th September, 2026. 路 21 Oct 2026
